Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0SFSCT
ADC Name
WO2024193682A1 32G1-2F11-ADC
Synonyms
32G1-2F11-ADC
   Click to Show/Hide
Organization
XADCERA BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
Drug Status
Investigative
Antibody Name
undisclosed
Antigen Name
Trophoblast glycoprotein (TPBG)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Animal Model (No. of PDX)
Tumor Growth lnhibition value (TGl) 
45.9
%
TPBG Patient-derived Xenograft Model
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth lnhibition value (TGl) 
59.2
%
Undisclosed Undisclosed
Tumor Growth lnhibition value (TGl) 
97.7
%
Undisclosed Undisclosed
Tumor Growth lnhibition value (TGl) 
98.7
%
Undisclosed Undisclosed
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) 45.90% Positive TPBG expression (TPBG+++/++)
Method Description
The patient-derived tumor firagments (2mmx2mmx2mm,TPBG positive cells constituted 58.86% and MET positive cells constituted 24.08% of total cells) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 3mg/kg (QW&#422,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 28.

   Click to Show/Hide
In Vivo Model TPBG Patient-derived Xenograft Model
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl)
59.20%
Method Description
Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 1x106 (NCI-H1975) tumor cells, and treatmen with 1.5mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 28.
In Vivo Model NCI-H1976 xenograft model
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl)
97.70%
Method Description
Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 5x106 (NUGC-4) tumor cells, and treatmen with 3mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 35.
In Vivo Model NUGC-4 xenograft model
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl)
98.70%
Method Description
Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 1x106 (NCI-H1975) tumor cells, and treatmen with 3mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 28.
In Vivo Model NCI-H1978 xenograft model
References
Ref 1 Anti-TPBG/MET antibodies and uses thereof